Search Within

Jose T Baselga

Formats
  1. Meeting Abstract (241)
  2. Journal Article (233)
  3. Conference Paper (4)
  4. Research Letter (3)
  5. Book Section (2)
  6. Review (1)
Groups
  1. Department of Medicine (197)
  2. Solid Tumor Oncology Division (192)
  3. Breast Medicine Service (149)
  4. GSK Faculty (128)
  5. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (108)
  6. Human Oncology and Pathogenesis Program (97)

More Groups

People
  1. David Hyman (68)
  2. Maurizio Scaltriti (63)
  3. Clifford Hudis (57)
  4. Michael Berger (56)
  5. Larry Norton (51)
  6. Sarat Chandarlapaty (48)

More People

Years
  1. 2021 (5)
  2. 2020 (11)
  3. 2019 (25)
  4. 2018 (58)
  5. 2017 (68)
  6. 2016 (67)

More Years

Publications
  1. Cancer Research (109)
  2. Journal of Clinical Oncology (92)
  3. Annals of Oncology (29)
  4. Clinical Cancer Research (29)
  5. European Journal of Cancer (25)
  6. Cancer Discovery (13)

More Publications

Publishers
  1. American Association for Cancer Research (163)
  2. American Society of Clinical Oncology (97)
  3. Oxford University Press (41)
  4. Elsevier Inc. (39)
  5. Nature Publishing Group (30)
  6. Springer (16)

More Publishers

Results (484)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • p95HER2-T cell bispecific antibody for breast cancer treatment
    Meeting Abstract

    Vicario, R.; Ruiz, I. R.; Morancho, B.; Morales, C. B.; Herter, S.; Freimoser-Grundscholber, A.; Somandin, J.; Sam, J.; Ast, O.; Barriocanal, A. M.; more...
    Cancer Research (2018)

    Fulltext@MSK | Save
  • Primary results from FAIRLANE (NCT02301988), a double-blind placebo (PBO)-controlled randomized phase II trial of neoadjuvant ipatasertib (IPAT) plus paclitaxel (PAC) for early triple-negative breast cancer (eTNBC)
    Meeting Abstract

    Oliveira, M.; Saura, C.; Calvo, I.; Andersen, J.; Coelho, J. L. P.; Gil, M. G.; Bermejo, B.; Patt, D. A.; Ciruelos, E.; Singel, S. M.; more...
    Cancer Research (2018)

    Fulltext@MSK | Save
  • A phase I basket study of the PI3K inhibitor taselisib (GDC-0032) in PIK3CA-mutated locally advanced or metastatic solid tumors
    Meeting Abstract

    Jhaveri, K.; Juric, D.; Saura, C.; Cervantes, A.; Melnyk, A.; Patel, M. R.; Oliveira, M.; Gambardella, V.; Ribrag, V.; Ma, C. X.; more...
    Cancer Research (2018)

    Fulltext@MSK | Save
  • Development of plasma cell-free DNA (cfDNA) assays for early cancer detection: First insights from the Circulating Cell-Free Genome Atlas Study (CCGA)
    Meeting Abstract

    Aravanis, A. A.; Oxnard, G. R.; Maddala, T.; Hubbell, E.; Venn, O.; Jamshidi, A.; Shen, L.; Amini, H.; Beausang, J. A.; Betts, C.; more...
    Cancer Research (2018)

    Fulltext@MSK | Save
  • On-treatment changes in circulating tumor DNA (ctDNA) level as an early predictor of clinical outcome in the LOTUS randomized phase 2 trial of 1st-line ipatasertib (IPAT) + paclitaxel (PAC) for metastatic triple-negative breast cancer (mTNBC)
    Meeting Abstract

    Wongchenko, M. J.; Lipson, D.; Clark, T.; Kennedy, M.; Greene, M.; Breese, V.; Tsiros, A.; Kim, S. B.; Saura, C.; Oliveira, M.; more...
    Cancer Research (2018)

    Fulltext@MSK | Save
  • Biomarkers of response to CDK4/6 inhibitor (CDK4/6i) in hormone receptor (HR) positive and HER2-positive breast cancer (BC) patient-derived xenografts (PDX)
    Meeting Abstract

    Palafox, M.; Herrera-Abreu, M. T.; Bellet, M.; Oliveira, M.; Bruna, A.; Rodriguez, O.; Guzman, M.; Grueso, J.; Vilaplana, C.; Arribas, J.; more...
    Cancer Research (2018)

    Fulltext@MSK | Save
  • Vemurafenib in patients with relapsed refractory multiple myeloma harboring BRAF(V600) mutations: A cohort of the histology-independent VE-BASKET study
    Journal Article

    Raje, N.; Chau, I.; Hyman, D. M.; Ribrag, V.; Blay, J. Y.; Tabernero, J.; Elez, E.; Wolf, J.; Yee, A. J.; Kaiser, M.; more...
    JCO Precision Oncology (2018)

    Fulltext@MSK | Save
  • Oncologic therapy for solid tumors alters the risk of clonal hematopoiesis
    Meeting Abstract

    Bolton, K.; Ptashkin, R.; Braunstein, L.; Kelly, D.; Devlin, S. M.; Coombs, C. C.; Moarii, M.; Patel, M.; Bernard, E.; Berthon, A.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Autoimmunity and benefit from trastuzumab treatment in breast cancer: Results from the HERA phase III trial
    Meeting Abstract

    Sonnenblick, A.; Bailey, A.; Uziely, B.; Untch, M.; Smith, I.; Gianni, L.; Baselga, J.; Jackisch, C.; Cameron, D.; Bell, R.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) v FULV in patients (pts) with estrogen receptor (ER)-positive, PIK3CA-mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPER
    Meeting Abstract

    Baselga, J.; Dent, S. F.; Cortés, J.; Im, Y. H.; Diéras, V.; Harbeck, N.; Krop, I. E.; Verma, S.; Wilson, T. R.; Jin, H.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save